GSA Capital Partners’s Unity Biotechnology UBX Stock Holding History

GSA Capital Partners’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-63,994	Closed	-$361K	–	1874
2022 Q2	$361K	Sell	63,994 -8,426	-12%	-$70.3K	0.05%	708
2022 Q1	$811K	Buy	72,420 +2,808	+4%	+$31.5K	0.11%	268
2021 Q4	$1.02M	Buy	69,612 +22,875	+49%	+$500K	0.13%	196
2021 Q3	$1.4M	Buy	46,737 +26,149	+127%	+$923K	0.14%	154
2021 Q2	$955K	Buy	+20,588	New	+$991K	0.11%	276
2020 Q4	–	Sell	-3,044	Closed	-$105K	–	1612
2020 Q3	$105K	Buy	+3,044	New	+$193K	0.02%	1130

Other funds holding UBX

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Empery Asset Management New York $86.5M AUM

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSA Capital Partners's UBX Position: Q3 2022 in Review

GSA Capital Partners sold out of Unity Biotechnology (UBX) in Q3 2022, closing a stake of 63,994 shares — an estimated $361K sold.

GSA Capital Partners first reported a position in UBX in Q3 2020 and held it in 6 quarters. The position peaked at $1.4M in Q3 2021. 72 funds tracked by Wall St. Rank hold UBX as of Q3 2022.

GSA Capital Partners reported no remaining Unity Biotechnology position as of Q3 2022 after selling out during the quarter.
GSA Capital Partners sold 63,994 Unity Biotechnology shares in Q3 2022, an estimated $361K.
GSA Capital Partners first reported a position in Unity Biotechnology in Q3 2020 and held it in 6 quarters.
GSA Capital Partners's Unity Biotechnology position peaked at $1.4M in Q3 2021.
72 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2022.

Based on GSA Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.